Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, IL-2, and CAPOX with Radiotherapy for Locally Advanced Rectal Cancer
NCT06577194Phase 2Active, not recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and aldesleukin in rectal cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Complete response rate (pCR or cCR) at 6 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
sintilimabaldesleukin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06577194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577194.